-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Insulin plays an important role in the treatment of diabetes, not only can effectively lower blood sugar, but also delay the appearance of complications
.
The "centralized insulin procurement" has a profound impact on the treatment of diabetes in China
.
With the opening of bids for the sixth batch of national centralized procurement of insulin drugs in Shanghai, China's biological drug procurement policy was first implemented in the field of diabetes
.
It is reported that in this round of centralized procurement, the second- and third-generation insulins that are commonly used in clinical injections are included in the centralized procurement, with an average drop of more than 47%, and about 10 million "sugar friends" will benefit from it
.
After the collection, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection (25R) dropped by 73% in price, opening the era of "within 20 yuan" for the third generation of insulin
.
This not only promotes the return of insulin prices to reasonable levels and benefits more patients, it is also of great significance for improving the centralized procurement system and achieving the reform goals
.
In addition, some people in the industry said that in this centralized procurement, Ganli Pharmaceutical became a big winner, and its six products were selected in the high order, and 3 products were selected in the first position, respectively, protamine and human insulin mixed injections.
The winning bids for liquid (30R), insulin glargine and insulin aspart were respectively 17.
89 yuan, 19.
98 yuan and 48.
71 yuan, and the price reductions reached 64%, 72% and 63% respectively
.
So how to plan insulin in the post-collective era? Ganli Pharmaceuticals stated that “the insulin market will enter the era of intensive cultivation
.
” According to relevant sources, Ganli Pharmaceuticals is currently focusing on several major tasks: 1.
To further ensure that the upstream industrial chain can be controlled and reduce costs, including self-production of raw materials and related products.
Quality upgrading of consumables and packaging materials, etc.
; 2.
Expansion of the sales market, including the primary market and overseas markets; 3.
Continue to increase R&D investment and deploy the entire product line
.
It is reported that Gan Li Pharmaceutical is promoting insulin, insulin aspart, and insulin lispro The three products are currently applying for FDA certification and are undergoing clinical trials overseas
.
Data shows that China's insulin market is highly concentrated
.
According to data from Meinenet, in 2020, the sales of terminal insulin and similar drugs in public medical institutions in China will be close to 27 billion yuan
.
Among the local companies, Ganli Pharmaceutical, Tonghua Dongbao, and Zhuhai Federation are giants, and Ganli Pharmaceutical's insulin market share will exceed 10% in 2020
.
The author was informed that, in addition to Ganli Pharmaceutical's disclosure of the company's plans for insulin in the post-centralized procurement era, Tonghua Dongbao also stated that it will deepen its efforts in the endocrine field and increase its deployment of innovative drug R&D pipelines
.
It is reported that Tonghua Dongbao has a comprehensive development pipeline for diabetes treatment products: including biological drugs insulin aspart 30 and 50 injections, insulin lispro 25R, 50R, insulin degludec, super fast-acting insulin lispro, and soluble glargine lispro di-insulin injection, liraglutide, Suoma Lu peptide
.
According to the industry, scientists have made continuous improvements in insulin over the past 100 years, and now insulin drugs have been improved to a very safe and convenient level
.
But insulin also has inconveniences, mainly in the way of administration
.
The person said that the current research directions on new insulin products can be summarized into two categories: first, the development of new delivery methods, such as oral insulin and inhaled insulin drugs; second, improving injection methods to make users painless
.
.
The "centralized insulin procurement" has a profound impact on the treatment of diabetes in China
.
With the opening of bids for the sixth batch of national centralized procurement of insulin drugs in Shanghai, China's biological drug procurement policy was first implemented in the field of diabetes
.
It is reported that in this round of centralized procurement, the second- and third-generation insulins that are commonly used in clinical injections are included in the centralized procurement, with an average drop of more than 47%, and about 10 million "sugar friends" will benefit from it
.
After the collection, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection (25R) dropped by 73% in price, opening the era of "within 20 yuan" for the third generation of insulin
.
This not only promotes the return of insulin prices to reasonable levels and benefits more patients, it is also of great significance for improving the centralized procurement system and achieving the reform goals
.
In addition, some people in the industry said that in this centralized procurement, Ganli Pharmaceutical became a big winner, and its six products were selected in the high order, and 3 products were selected in the first position, respectively, protamine and human insulin mixed injections.
The winning bids for liquid (30R), insulin glargine and insulin aspart were respectively 17.
89 yuan, 19.
98 yuan and 48.
71 yuan, and the price reductions reached 64%, 72% and 63% respectively
.
So how to plan insulin in the post-collective era? Ganli Pharmaceuticals stated that “the insulin market will enter the era of intensive cultivation
.
” According to relevant sources, Ganli Pharmaceuticals is currently focusing on several major tasks: 1.
To further ensure that the upstream industrial chain can be controlled and reduce costs, including self-production of raw materials and related products.
Quality upgrading of consumables and packaging materials, etc.
; 2.
Expansion of the sales market, including the primary market and overseas markets; 3.
Continue to increase R&D investment and deploy the entire product line
.
It is reported that Gan Li Pharmaceutical is promoting insulin, insulin aspart, and insulin lispro The three products are currently applying for FDA certification and are undergoing clinical trials overseas
.
Data shows that China's insulin market is highly concentrated
.
According to data from Meinenet, in 2020, the sales of terminal insulin and similar drugs in public medical institutions in China will be close to 27 billion yuan
.
Among the local companies, Ganli Pharmaceutical, Tonghua Dongbao, and Zhuhai Federation are giants, and Ganli Pharmaceutical's insulin market share will exceed 10% in 2020
.
The author was informed that, in addition to Ganli Pharmaceutical's disclosure of the company's plans for insulin in the post-centralized procurement era, Tonghua Dongbao also stated that it will deepen its efforts in the endocrine field and increase its deployment of innovative drug R&D pipelines
.
It is reported that Tonghua Dongbao has a comprehensive development pipeline for diabetes treatment products: including biological drugs insulin aspart 30 and 50 injections, insulin lispro 25R, 50R, insulin degludec, super fast-acting insulin lispro, and soluble glargine lispro di-insulin injection, liraglutide, Suoma Lu peptide
.
According to the industry, scientists have made continuous improvements in insulin over the past 100 years, and now insulin drugs have been improved to a very safe and convenient level
.
But insulin also has inconveniences, mainly in the way of administration
.
The person said that the current research directions on new insulin products can be summarized into two categories: first, the development of new delivery methods, such as oral insulin and inhaled insulin drugs; second, improving injection methods to make users painless
.
